These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 16038709)

  • 1. Probing p53 biological functions through the use of genetically engineered mouse models.
    Attardi LD; Donehower LA
    Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into aging obtained from p53 mutant mouse models.
    Dumble M; Gatza C; Tyner S; Venkatachalam S; Donehower LA
    Ann N Y Acad Sci; 2004 Jun; 1019():171-7. PubMed ID: 15247009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53-deficient mouse: a model for basic and applied cancer studies.
    Donehower LA
    Semin Cancer Biol; 1996 Oct; 7(5):269-78. PubMed ID: 9110404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into cancer from transgenic mouse models.
    Macleod KF; Jacks T
    J Pathol; 1999 Jan; 187(1):43-60. PubMed ID: 10341706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
    Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
    Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer.
    Zhang Z; Wang Y; Yao R; Li J; Lubet RA; You M
    Mol Cancer Res; 2006 Jun; 4(6):401-10. PubMed ID: 16778087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
    Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
    Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung-specific expression in mice of a dominant negative mutant form of the p53 tumor suppressor protein.
    Morris GF; Hoyle GW; Athas GB; Lei WH; Xu J; Morris CB; Friedman M
    J La State Med Soc; 1998 Apr; 150(4):179-85. PubMed ID: 9610073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.
    Farazi PA; Glickman J; Horner J; Depinho RA
    Cancer Res; 2006 May; 66(9):4766-73. PubMed ID: 16651430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation.
    McAllister KA; Houle CD; Malphurs J; Ward T; Collins NK; Gersch W; Wharey L; Seely JC; Betz L; Bennett LM; Wiseman RW; Davis BJ
    Toxicol Pathol; 2006; 34(2):187-98. PubMed ID: 16546942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced susceptibility to chemical induction of ovarian tumors in mice with a germ line p53 mutation.
    Wang Y; Zhang Z; Lu Y; Yao R; Jia D; Wen W; LaRegina M; Crist K; Lubet R; You M
    Mol Cancer Res; 2008 Jan; 6(1):99-109. PubMed ID: 18234966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53.
    Jaworski M; Hailfinger S; Buchmann A; Hergenhahn M; Hollstein M; Ittrich C; Schwarz M
    Carcinogenesis; 2005 Oct; 26(10):1829-34. PubMed ID: 15917304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells.
    Ridgeway AG; McMenamin J; Leder P
    Oncogene; 2006 Jun; 25(25):3518-27. PubMed ID: 16434961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mild mutator phenotype arises in a mouse model for malignancies associated with neurofibromatosis type 1.
    Garza R; Hudson RA; McMahan CA; Walter CA; Vogel KS
    Mutat Res; 2007 Feb; 615(1-2):98-110. PubMed ID: 17208258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous and engineered mutant mice as models for experimental and comparative pathology: history, comparison, and developmental technology.
    Roths JB; Foxworth WB; McArthur MJ; Montgomery CA; Kier AB
    Lab Anim Sci; 1999 Feb; 49(1):12-34. PubMed ID: 10090091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse models with modified p53 sequences to study cancer and ageing.
    Clarke AR; Hollstein M
    Cell Death Differ; 2003 Apr; 10(4):443-50. PubMed ID: 12719721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of p53 mutant mice.
    Dumble ML; Donehower LA; Lu X
    Methods Mol Biol; 2003; 234():29-49. PubMed ID: 12824523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rhabdomyosarcoma development in Trp53/fos mutant mice: tumor suppressor functions of the Fos protooncogene].
    Jochum W
    Verh Dtsch Ges Pathol; 2004; 88():224-30. PubMed ID: 16892556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
    Biggs PJ; Vogel H; Sage M; Martin LA; Donehower LA; Bradley A
    Oncogene; 2003 May; 22(21):3288-96. PubMed ID: 12761499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.